{"id":780334,"date":"2021-09-30T07:25:25","date_gmt":"2021-09-30T14:25:25","guid":{"rendered":"https:\/\/cm-edgetun.pages.dev\/en-us\/research\/?post_type=msr-blog-post&#038;p=780334"},"modified":"2021-09-30T07:43:38","modified_gmt":"2021-09-30T14:43:38","slug":"an-alphavirus-derived-replicon-rna-vaccine-induces-sars-cov-2-neutralizing-antibody-and-t-cell-responses-in-mice-and-nonhuman-primates","status":"publish","type":"msr-blog-post","link":"https:\/\/cm-edgetun.pages.dev\/en-us\/research\/articles\/an-alphavirus-derived-replicon-rna-vaccine-induces-sars-cov-2-neutralizing-antibody-and-t-cell-responses-in-mice-and-nonhuman-primates\/","title":{"rendered":"An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates"},"content":{"rendered":"<p>The coronavirus disease 2019 (COVID-19) pandemic, caused by infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is having a deleterious impact on health services and the global economy, highlighting the urgent need for an effective vaccine. Such a vaccine would need to rapidly confer protection after one or two doses and would need to be manufactured using components suitable for scale up. Here, we developed an Alphavirus-derived replicon RNA vaccine candidate, repRNA-CoV2S, encoding the SARS-CoV-2 spike (S) protein.<br \/>\n<a class=\"msr-external-link glyph-append glyph-append-open-in-new-tab glyph-append-xsmall\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32690628\/\" rel=\"noopener noreferrer\" target=\"_blank\">https:\/\/pubmed.ncbi.nlm.nih.gov\/32690628\/<span class=\"sr-only\"> (opens in new tab)<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The coronavirus disease 2019 (COVID-19) pandemic, caused by infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is having a deleterious impact on health services and the global economy, highlighting the urgent need for an effective vaccine. Such a vaccine would need to rapidly confer protection after one or two doses and would need to [&hellip;]<\/p>\n","protected":false},"author":37625,"featured_media":0,"template":"","meta":{"msr-url-field":"","msr-podcast-episode":"","msrModifiedDate":"","msrModifiedDateEnabled":false,"ep_exclude_from_search":false,"_classifai_error":"","msr-content-parent":669339,"msr_hide_image_in_river":0,"footnotes":""},"research-area":[],"msr-locale":[268875],"msr-post-option":[],"class_list":["post-780334","msr-blog-post","type-msr-blog-post","status-publish","hentry","msr-locale-en_us"],"msr_assoc_parent":{"id":669339,"type":"group"},"_links":{"self":[{"href":"https:\/\/cm-edgetun.pages.dev\/en-us\/research\/wp-json\/wp\/v2\/msr-blog-post\/780334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cm-edgetun.pages.dev\/en-us\/research\/wp-json\/wp\/v2\/msr-blog-post"}],"about":[{"href":"https:\/\/cm-edgetun.pages.dev\/en-us\/research\/wp-json\/wp\/v2\/types\/msr-blog-post"}],"author":[{"embeddable":true,"href":"https:\/\/cm-edgetun.pages.dev\/en-us\/research\/wp-json\/wp\/v2\/users\/37625"}],"version-history":[{"count":2,"href":"https:\/\/cm-edgetun.pages.dev\/en-us\/research\/wp-json\/wp\/v2\/msr-blog-post\/780334\/revisions"}],"predecessor-version":[{"id":780382,"href":"https:\/\/cm-edgetun.pages.dev\/en-us\/research\/wp-json\/wp\/v2\/msr-blog-post\/780334\/revisions\/780382"}],"wp:attachment":[{"href":"https:\/\/cm-edgetun.pages.dev\/en-us\/research\/wp-json\/wp\/v2\/media?parent=780334"}],"wp:term":[{"taxonomy":"msr-research-area","embeddable":true,"href":"https:\/\/cm-edgetun.pages.dev\/en-us\/research\/wp-json\/wp\/v2\/research-area?post=780334"},{"taxonomy":"msr-locale","embeddable":true,"href":"https:\/\/cm-edgetun.pages.dev\/en-us\/research\/wp-json\/wp\/v2\/msr-locale?post=780334"},{"taxonomy":"msr-post-option","embeddable":true,"href":"https:\/\/cm-edgetun.pages.dev\/en-us\/research\/wp-json\/wp\/v2\/msr-post-option?post=780334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}